Promising Three-Drug cocktail shows strong results in multiple myeloma

NCT ID NCT07206810

Completed Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested a combination of three drugs—bortezomib, lenalidomide, and dexamethasone (VRD)—in 419 newly diagnosed multiple myeloma patients. Some patients also received a stem cell transplant. The goal was to see how well the treatment worked and how long patients lived. The study found that the VRD regimen led to good response rates, but long-term follow-up is needed to confirm lasting benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bortezomib, lenalidomide, and dexamethasone (VRD)
What this could lead to: If successful, this regimen could become a standard first-line treatment for newly diagnosed multiple myeloma, improving response rates and extending survival.
What could go wrong: This is a single-center, real-world registry study, not a randomized controlled trial. Results may not apply to all patients, and long-term side effects of the drugs (e.g., nerve damage, blood clots) are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA

Contacts and locations

Locations

First Affiliated Hospital, Soochow University

Suzhou, Jiangsu, 215000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.